What happened
Glenmark Pharmaceuticals reported consolidated revenue from operations of Rs. 4,247.32 crore for the quarter ended September 30, 2026. This was 29.8% lower than the Rs. 6,046.87 crore reported in Q2 FY26.
However, the company also reported around 20% growth on a like-for-like basis in Q2 FY27. This is the number investors should examine before judging the business. The reported decline is affected by deferred out-licensing income linked to ISB 2001, an experimental cancer drug licensed to AbbVie.
North America shows this difference most clearly. Reported revenue from the region fell 72.9% to Rs. 1,208.9 crore in Q2 FY27. But the core business grew around 31% in Q2 FY27 after excluding the deferred licensing income recognition.
Profit was weaker. Consolidated profit after tax fell 56.78% to Rs. 263.83 crore in Q2 FY27 from Rs. 610.43 crore in Q2 FY26. Adjusted PAT for Q2 FY27, which excludes exceptional items, was Rs. 485.2 crore. EBITDA in Q2 FY27 stood at Rs. 863.8 crore, with a margin of 20.3%.
The quarter also included a USD 15 million settlement during Q2 FY27 between Glenmark's US subsidiary and Humana Inc. The settlement related to allegations of anti-competitive conduct in the generic drug market. This was an additional cost during the period, although the settlement did not amount to an admission of liability.
The results therefore show two different trends. Glenmark's underlying business continued to grow, but reported earnings faced pressure from exceptional items and a difficult comparison with the previous year.
Why does revenue explained matter for pharmaceutical stocks?
Revenue tells investors how much a company earns from its business. But it does not always show how well that business is performing.
Pharmaceutical companies often earn money through product sales, licensing deals, milestone payments and partnerships. These income sources do not always follow the same pattern. A large payment recognised in one year can also make the next year's growth look weak.
Glenmark is a good example. Its reported revenue fell almost 30% in Q2 FY27, yet its like-for-like growth was around 20% in Q2 FY27. The difference matters because it changes how investors read the company's performance.
Regional sales offer another useful clue. India formulations grew around 14% on a like-for-like basis in Q2 FY27. Europe's business grew 6.2% in Q2 FY27. Emerging Markets expanded 33.2% in Q2 FY27. North America's core business grew around 31% in Q2 FY27 after adjusting for the licensing income recognition.
But revenue growth alone is not enough. Glenmark's EBITDA margin was 20.3% in Q2 FY27, and its reported PAT was much lower than its adjusted PAT. Investors must ask whether sales growth can lead to better margins and cash generation.
This is the real purpose of revenue explained: separating changes in reported income from changes in the underlying business. In broader stock market explained terms, it helps investors avoid treating every fall in quarterly sales as a sign of business failure.
For a broader look at how company performance and market risks affect investment decisions, read Vestmind's stock analysis methodology.
What are the exact figures behind Glenmark's Q2 FY27 results?
Glenmark's quarterly results show a clear gap between reported performance and underlying growth.
The main financial figures are:
• Consolidated revenue: Rs. 4,247.32 crore in Q2 FY27, down 29.8% year-on-year. • Like-for-like consolidated revenue growth: approximately 20% in Q2 FY27. • Reported PAT: Rs. 263.83 crore in Q2 FY27, down 56.78% year-on-year. • Adjusted PAT for Q2 FY27: Rs. 485.2 crore. • EBITDA for Q2 FY27: Rs. 863.8 crore. • EBITDA margin in Q2 FY27: 20.3%. • Consolidated R&D spending in Q2 FY27: Rs. 344.9 crore.
Regional sales also reveal important differences.
India formulations generated Rs. 1,327.4 crore in revenue in Q2 FY27. The like-for-like growth rate was around 14% in Q2 FY27. North America reported Rs. 1,208.9 crore in Q2 FY27, down 72.9%, but its core business grew around 31% in Q2 FY27. Europe generated Rs. 792 crore in Q2 FY27, up 6.2%. Emerging Markets recorded Rs. 876.9 crore in Q2 FY27, up 33.2%.
One important detail is the gap between adjusted and reported PAT. The company reported adjusted PAT of Rs. 485.2 crore for Q2 FY27 after excluding exceptional items. Reported PAT for Q2 FY27 was Rs. 263.83 crore. Investors should not treat these figures as interchangeable. Reported earnings include the impact of exceptional charges.
Glenmark also maintained its FY27 guidance. It expects consolidated revenue of Rs. 17,000-18,000 crore, with margins of 21-22%. These targets give investors a clear benchmark for tracking the next two quarters.
What does this mean for your portfolio?
Glenmark's results offer an important lesson in why having revenue explained matters when reading quarterly earnings. A sharp fall in reported revenue does not always mean the core business is shrinking.
An investor looking only at the 29.8% revenue decline in Q2 FY27 might conclude that Glenmark is losing ground. But its 20% like-for-like growth in Q2 FY27 tells a different story. The North American recovery and growth across Emerging Markets also support this view.
However, there are risks. EBITDA margin fell sharply from the previous year's level. Reported PAT also remained well below adjusted PAT. The company must now show that its sales growth can support stronger profits.
Investors holding pharma stocks should also check their sector exposure. A portfolio with several drug companies may still carry high risk if those companies depend on the same export markets or product categories.
This is where the idea of havens explained in asset allocation becomes relevant, but with an important distinction. Defensive sectors are not risk-free. Pharmaceutical stocks can face regulatory action, pricing pressure, legal costs and delays in product approvals. They should not be treated as automatic safe havens during market volatility.
Review the weight of pharmaceutical stocks in your portfolio. Also check the underlying companies held by your mutual funds. This helps you see whether you have more exposure to one company or sector than you intended.
Vestmind's view
With Glenmark's revenue explained, the Q2 FY27 results are better than the headline revenue decline suggests, but they are not an all-clear signal.
The positive case rests on three factors. Like-for-like revenue grew around 20% in Q2 FY27. North America's core business expanded 31% in Q2 FY27. Emerging Markets delivered 33.2% growth in Q2 FY27. These numbers suggest that the company's base business has momentum.
The concern is profitability. EBITDA margin stood at 20.3% in Q2 FY27, and reported PAT fell 56.78% in Q2 FY27. The gap between adjusted and reported earnings also shows why investors must look closely at exceptional costs.
We would become more positive if Glenmark sustains its regional growth, improves margins and meets its FY27 guidance. We would turn cautious if sales momentum slows or earnings remain weak despite higher revenue.
Our conclusion: the market should not judge Glenmark only by its 29.8% reported revenue decline. But the company must now prove that strong underlying growth can translate into lasting profit growth.
What to watch next
Three developments will matter most in Glenmark's next results.
First, watch North America. Its core business grew around 31% in Q2 FY27 after excluding deferred licensing income. Investors should check whether new product launches can sustain this recovery.
Second, track operating margins and reported profit. EBITDA margin stood at 20.3% in Q2 FY27. Adjusted PAT for Q2 FY27 was Rs. 485.2 crore, against reported PAT of Rs. 263.83 crore. Stronger margins and a smaller gap between adjusted and reported earnings would improve confidence in the quality of profits.
Third, follow the oncology pipeline. Glenmark expects the first commercial launch from its partnered innovative oncology pipeline by the end of FY27. Its innovation subsidiary has also selected Phase 1 data for ISB 2001 for an oral presentation at the 2026 American Society of Hematology meeting. The company plans to submit an investigational new drug application for ISB 2301 by the end of calendar year 2026.
Also watch RYALTRIS, its international launches and the company's progress towards FY27 revenue guidance of Rs. 17,000-18,000 crore.
The next two quarters will help answer the bigger question: can Glenmark turn strong underlying sales growth into stronger and more consistent earnings?

Comments
Log in to join the discussion.